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The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaBackground & Aims: Hepatitis B virus (HBV) RNA in serum has
recently been linked to efficacy and prognosis of chronic hepatitis
after blocking the encapsidation of pgRNA. Furthermore, the
presence of HBV pgRNA virion was associated with risk of viralB (CHB) treatment. This study explored the nature, origin, under-
lying mechanisms, and potential clinical significance of serum
HBV RNA.
Methods: The levels of HBV DNA and RNA were determined in
the supernatant of induced HepAD38, HBV-expressing
HepG2.2.15 cells and primary human hepatocytes (PHH), and in
the serum of transgenic mice and CHB patients. NP-40 and pro-
teinase K treatment, sucrose density gradient centrifugation,
electron microscopy, northern blot, multiple identification PCRs
and 50 rapid-amplification of cDNA ends were performed to iden-
tify the nature of serum HBV RNA.
Results: Although significantly lower than HBV DNA levels, abun-
dant HBV RNA was present in the serum of CHB patients. A series
of experiments demonstrated that serum HBV RNA was prege-
nome RNA (pgRNA) and present in virus-like particles. HBV
pgRNA virion levels increased after blocking the reverse
transcription activity of HBV DNA polymerase, and decreasedJournal of Hepatology 20
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Conclusions: Serum HBV RNA was confirmed to be pgRNA pre-
sent in virus-like particles. HBV pgRNA virions were produced
from encapsidated particles in which the pgRNA was non- or par-
tially reverse transcribed. Clinically, HBV pgRNA virion might be a
potential biomarker for monitoring safe discontinuation of NA-
therapy.
Lay summary: HBV may have another virion form in which the
nucleic acid is composed of RNA, not DNA. The level of HBV
RNA virion in serum may be associated with risk of HBV viral
rebound after withdrawal of treatment, and therefore, a potential
predictive biomarker to monitor the safe discontinuation of
nucleot(s)ide analogues-therapy.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis B virus (HBV) infection is a serious global public health
problem with more than two billion people infected with HBV
worldwide. It is estimated that every year 786,000 people will
die of chronic HBV infection-related diseases including liver cir-
rhosis or hepatocellular carcinoma (HCC) [1–3].
HBV belongs to the Hepadnaviridae family, which are defined
as double-stranded DNA viruses replicating their DNA genome
through reverse transcription from pre-genomic RNA (pgRNA).16 vol. 65 j 700–710
Table 1. Clinical background of the patient cohort A.
Characteristics Values
Gender (M:F) 7:4
Age (years)a 39 (24-52)
ALT (IU/L)a 141 (65-318)
HBV DNA (log10 copies/ml)
a 7.87 (6.56-9.01)
HBsAg (IU/ml)a 15,695 (1221-196,392)
HBeAg (S/CO)a 1846 (83-4528)
NAs LdT
Duration of NAs therapy (weeks)a 236 (24-268)
aMedian (range). NAs, nucleot(s)ide analogues; TBV, telbivudine.
Table 2. Clinical background of the patient cohort B.
Characteristics DNA rebound
(n = 24)
DNA non-rebound
(n = 9)
Gender (M:F) 2:1 5:4
Age (years) 33 (18-54) 28 (23-59)
NAs LMV/ETV/ADV/LdT LMV/ETV/ADV/ LdT
End of treatment
HBV DNA
(log10 copies/ml)
below the LoD below the LoD
HBsAg (IU/ml) 1503 (80.01-22,486) 329.8 (0.05-41,280)
HBeAg (S/CO) 0.120 (0.075-0.929) 0.112 (0.086-0.387)
HBeAb (S/CO) 0.024 (0.004-1.06) 0.007 (0.004-1.3)
AST (IU/L) 24 (14-44) 21 (15-28)
ALT (IU/L) 24 (11-45) 16 (6-21)
24 weeks post EoT
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During viral morphogenesis, pgRNA is encapsidated into core
particles and reverse transcribed by HBV DNA polymerase into
rcDNA. Mature rcDNA-containing virions are then enveloped
and released from infected hepatocytes [4–6]. Importantly, in
addition to HBV DNA, HBV RNA has also been detected in the
serum of chronic hepatitis B (CHB) patient [7–14]. However, the
life cycle of HBV cannot fully explain the generation of serum
HBV RNA.
While nucleot(s)ide analogues (NAs) like entecavir (ETV) and
tenofovir can significantly inhibit HBV replication and decrease
serum HBV DNA to undetectable level, it is still difficult to
achieve clinical cure of CHB due to the persistence of covalently
closed circular DNA (cccDNA) in the nuclei of infected cells
[15,16]. Once treatment is discontinued, a relapse in HBV levels
is observed. Therefore, CHB patients require a long-term treat-
ment. Unfortunately, long-term treatment with NAs possessing
a low barrier to resistance, such as lamivudine, may lead to the
appearance of drug-resistant viral mutants and subsequent risk
of serious hepatitis flare-ups [17]. Thus, how and when to adjust
the treatment regimen is a key point during the treatment of
CHB. In this context, serum HBV RNA has been reported as an
important potential predictor of the tyrosine-methionine-
aspartate-aspartate (YMDD) resistance mutation [11], efficacy
[9,12–14] and prognosis [10] of CHB treatment. Whether
dynamic changes in serum HBV RNA can be used as a potential
marker for the safe discontinuation of NAs-therapy remains an
open question.
In this study, the nature and origin of serum HBV RNA was
investigated in both in vitro and in vivo experiments to mechanis-
tically determine the potential clinical significance of HBV RNA in
serum.HBV DNA
(log10 copies/ml)
5.00 (2.26-8.35) below the LoD
HBsAg (IU/ml) 2444 (74.4-19,280) 77.6 (0.05-2820)
HBeAg (S/CO) 0.101 (0.076-0.481) 0.141 (0.125-0.179)
HBeAb (S/CO) 0.004 (0.003-0.985) 0.92 (0.003-1.65)
AST (IU/L) 27 (16-330) 24 (18-30)
ALT (IU/L) 29 (6-610) 18 (13-23)
LMV, lamivudine, ETV, enticavir, ADV, adefovir dipivoxil, LdT, telbivudine, LoD,
lower limit of detection.Material and methods
Cell lines
The human liver cancer cell line HuH7 [18], the stable HBV-expressing human
liver cancer cell lines HepG2.2.15 [19] and HepAD38 cells [20] were all main-
tained in Dulbecco’s modified eagle medium supplemented with 10% fetal bovine
serum (Gibco, Carlsbad, Calif, USA).
Primary human hepatocytes (PHH)
PHH were kindly provided by Professor Hongkui Deng from the Department of
Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell
Research Center. The cells were maintained in primary hepatocytes maintenance
medium (PMM) as previously described [21].
Patient specimens
Patient cohort A included 11 Han Chinese CHB patients who had received tel-
bivudine (TBV) therapy for more than 6 months at the Second Affiliated Hospital
of Chongqing Medical University. The clinical background of the patients in
cohort A is shown in Table 1. Patient cohort B included 33 Han Chinese CHB
patients who had received NA-therapy for more than 3 years at the Third Affili-
ated Hospital of Sun Yat-Sen University and subsequently discontinued NA-
therapy. The discontinuation of NA-therapy in all cases was decided by the
attending physician with use of similar but not uniform criteria. The clinical back-
ground of the patients in cohort B is shown in Table 2. The experimental protocol
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. This
study was approved by the Ethics Committee of Peking University Health Science
Center. Written informed consent was obtained from each patient.Journal of Hepatology 201Transgenic mice
The HBV transgenic (HBV-Tg) mice were provided by Pei-Jer Chen from the
Department of Internal Medicine, National Taiwan University Hospital, National
Taiwan University College of Medicine [22]. All mice were maintained under
specific pathogen-free conditions in the Laboratory Animal Center of Xiamen
University. The experiments were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals.
Compounds
Entecavir (ETV) crude drug was kindly provided by Fujian Cosunter pharmaceu-
tical company (Fuzhou, Fujian, China) or Acme Biosciences (Palo Alto, CA, USA),
and was dissolved in N, N-Dimethylacetamide (Sigma-Aldrich, St. Louis, MO,
USA) to generate a 100 mM stock solution and stored at 20 C. GLS4 was synthe-
sized by published procedures [23], and was dissolved in dimethyl sulfoxide
(DMSO) (Sigma-Aldrich, St. Louis, MO, USA) to generate a 2 mM to 100 mM stock
solution and stored at 20 C.6 vol. 65 j 700–710 701
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Plasmids
The 1.2 x HBV construct (pBB4.5-HBV1.2, genotype C) was constructed using a 1.2-
fold length genome of genotype C HBV DNA based on pBB4.5-HBV1.2 (genotype D,
G1896A mutation) which was kindly provided by Professor Locarnini, from the
Victorian Infectious Diseases Reference Laboratory, Australia [24]. A mutant
plasmid carrying the Y63F mutation was generated from pBB4.5-HBV1.2 using
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Primer
sequences were: Forward: 50-GTGGGAAACTTTACTGGGCTTTTCTCTTCTACTGTACC
TATCTTTAATCC-30 . Reverse: 50-GGATTAAAGATACAGTAGAAGAGAAAAGCCCAGTA
AAGTTTCCCAC-30 .
HBV infection
HBV infection of PHH was conducted as previously described [25]. Briefly, 1  105
PHH cells in a 48-well plate were inoculated with 1  107 copies of genome
equivalent HBV in the presence of 4% PEG 8000 for 20 h. PHH cells were then
washed with PBS six times and maintained in PMM medium with medium
change every 2–3 days.
Extraction and reverse transcription of HBV RNA
HBV RNA was isolated using the EasyPure Viral RNA Kit (TransGen Biotech, Bei-
jing, China) according to the manufacturer’s instructions and treated with DNase I
(Thermo Fisher Scientific, Waltham, MA, USA). Isolated HBV RNA was reverse
transcribed using RevertAidTM First Strand DNA Synthesis Kit (Thermo Fisher
Scientific, Waltham, MA, USA) with either random primers or an HBV specific
RT primer. The sequence of HBV specific RT primer was: 50-ATTCTCAGACCGTAG
CACACGACACCGAGATTGAGATCTTCTGCGAC-30 in which the random sequence
ATTCTCAGACCGTAGCACACGACAC was anchored at the 50 end of HBV specific
sequence CGAGATTGAGATCTTCTGCGAC (nucleotide [nt] 2436-2415) and used
for detection of the 3.5 kb HBV RNA, or: 50-ATTCTCAGACCGTAGCACACGA
CACGCCTCAAGGTCGGTCGTTGAC-30 in which the random sequence ATTCTCAG
ACCGTAGCACACGACAC was anchored at the 50 end of HBV specific sequence
GCCTCAAGGTCGGTCGTTGAC (nt 1702-1682) and used for detection of total
HBV RNA.
Multiple identification PCRs
According to the difference of nucleotide sequence between preC mRNA and
pgRNA, we designed preC mRNA and 3.5 kb HBV RNA-specific primers. The
sequences of 3.5 kb RNA and preC mRNA specific forward primer were: F (nt
1856-1877): 50-CCTACTGTTCAAGCCTCCAAGC-30 , and F (nt 1796-1813): 50-GGTC
TGTTCACCAGCACC-30 , respectively. Both of the reverse primer was the anchored
random sequence: 50-ATTCTCAGACCGTAGCACACGACAC-30 . PCR reaction mixture
(20 ll) contained 10 ll 2Taq mix (GenStar, Beijing, China), 1 ll forward primer
(10 lM), 1 ll reverse primer (10 lM), 1 ll cDNA template and 7 ll double dis-
tilled water (ddH2O). The reaction mixture was denatured at 95 C for 5 min fol-
lowed by 35 cycles at 95 C for 30 s, 60 C for 30 s, 72 C for 45 s, and at last 72 C
for 7 min. DNA fragments of varying lengths were resolved by a 1.5% agarose gel.
Quantification of HBV RNA and HBV DNA
The levels of HBV RNA were detected by quantitative real-time polymerase chain
reaction (qPCR) in LightCycler 480 II Real-time PCR Detection System (Roche,
Mannheim, Germany) with a SYBR Green or TaqMan probe method. The primers
and probe used to detect HBV 3.5 kb RNA were as follows: F1 (nt 2295-2312): 50-
AYAGACCATCAAATGCCC-30 , R1 (Anchored sequence): 50-ATTCTCAGACCGTAGCA
CACGACAC-30 and probe: 50 FAM-CTTATCAACACTTCCGGARACTACTGTTGTTA
GAC-BHQ1-30 . The primers and probe used to detect HBV total RNA were as fol-
lows: F1 (nt 1554-1572): 50-TGTGCCTTCTCATCTGCCG-30 , R1 (Anchored
sequence): 50-ATTCTCAGACCGTAGCACACGACAC-30 and probe: 50 FAM-CGTGTGC
ACTTCGCTTCACCTCTGC-BHQ1-30 . The standards were constructed by PCR using
each primer from HepAD38 cDNA, and the PCR products were subsequently
ligated into the pEASY-Blunt Cloning Vector (TansGen, Beijing, China). The qPCR
reaction mixture (30 ll) contained 15 ll 2 x mix (LightCycler480 Probes Master,
Roche, Mannheim, Germany), 1 ll forward primer (10 lM), 1 ll reverse primer
(10 lM), 1 ll TaqMan probe (10 lM), 3 ll cDNA template and 9 ll double dis-
tilled water (ddH2O). The reaction mixture was denatured at 95 C for 5 min, fol-
lowed by 40 cycles at 95 C for 20 s, 60 C for 40 s. The level of HBV DNA was
quantified by the COBAS TaqMan 48 assay (Roche).702 Journal of Hepatology 201Quantification of HBsAg and HBeAg
The level of HBsAg and HBeAg was measured by a time-resolved fluoroim-
munoassay (TRFIA) as previously described [16] or by a commercial enzyme-
linked immunosorbent assay (Wantai Biological Pharmacy Enterprise Co., Beijing,
China).
PEG-precipitation
6 x PEG8000 buffer (48% PEG8000 and 200 mM NaCl) was added to the cellular
lysate or supernatant of HepAD38 cells at a volume ratio of 1 to 5. The mixture
was shaken slowly overnight at 4 C, and then centrifuged at 7500 rpm
(7232 g) with the brake ‘‘5” for 30 min at 10 C in an Eppendorf HL019 rotor
(Centrifuge 5810 R, Eppendorf, Germany). The PEG-precipitated pellet was
digested with Micrococcal Nuclease (New England Biolabs (NEB), Ipswich, MA,
USA) and proceeded for DNA/RNA extraction, Western Blot analysis, or sucrose
density gradient centrifugation.
Sucrose density gradient centrifugation
Sucrose density gradient centrifugation was performed as previously described
[26]. Briefly, discontinuous sucrose density gradients (15, 25, 35, 45 and 60%)
were prepared with a solution containing 20 mM Tris-HCl (pH 7.4), 140 mM NaCl
and 1 mM EDTA. Culture supernatant was laid on the linear sucrose gradient, and
centrifuged at 25,000 rpm (112,000 g) for 15 h at 10 C in a Beckman SW50.1
rotor (Beckman Coulter, Fullerton, CA, USA).
Electron microscopy
For conventional transmission electron microscopic observation, a drop of frac-
tion 26 separated by sucrose density gradient centrifugation was placed on a
carbon-coated 200-mesh copper grid. The grid was negatively stained with phos-
photungstic acid (1%, pH 6.8) for 1 min, and then examined by a transmission
electron microscope (FEI-TECNAI12, New York, USA) at 80 kV.
Northern blot
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was added to the virus pellet fol-
lowing PEG-precipitation, and total RNA was prepared in accordance to the man-
ufacturer’s instructions. RNA was mixed with denaturation buffer and heated at
65 C for 10 min, and immediately transferred to an ice bath. Denatured samples
were resolved on a 1.2% agarose gel in 1 x MOPS buffer at 70 V for 3 h. RNA in the
gel was transferred to nylon membrane for 1.5–2 h by vacuum. After transfer, the
membrane was UV cross-linked for 10 min. Pre-hybridization was performed in
pre-warmed ‘‘DIG Easy Hyb buffer” at 50 C for 2 h with gentle agitation. For
hybridization, the membrane was gently agitated in pre-warmed ‘‘DIG Easy
Hyb buffer” containing the DNA probe that had been denatured by boiling for
5 min. The membrane was washed by 2 x SSC/0.1% sodium dodecyl sulfate, and
then 0.5 x saline sodium citrate/0.1%SDS at 60 C and rinsed with 1 x maleic acid
buffer for 5 min. The membrane was blocked in 1% blocking buffer for 30 min and
incubated in anti-DIG antibody solution for 1 h, followed by rinsing with 1 x
washing buffer and incubating in 1 x detection buffer for 5 min. Finally, the mem-
brane was incubated with CDP-star and exposed.
Western blot
PEG-precipitated pellets from HepAD38 cells or supernatant were dissolved in 1x
Laemmli buffer (with 5% 2-mercaptoethanol), boiled for 10 min at 95 C and
resolved on 4–20% gradient SDS-PAGE gel (BioRad). HBV core protein was
detected with anti-Core antibody (DAKO, Denmark, or a gift from State Key Lab-
oratory of Molecular Vaccinology and Molecular Diagnostics, School of Public
Health, Xiamen University. Xiamen, Fujian, China).
Rapid-amplification of cDNA ends (RACE)
HBV RNA in fraction 26 of sucrose density gradient centrifugation was isolated
using the EasyPure Viral RNA Kit (TransGen Biotech, Beijing, China) according
to the manufacturer’s instructions, and treated with DNase I (Thermo Fisher Sci-
entific, Waltham, MA, USA). RACE amplification was performed using the SMAR-
TerTM RACE cDNA Amplification Kit (Clontech, Laboratories, Inc., Mountain View,6 vol. 65 j 700–710
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CA, USA) according to the manufacturer’s instructions. Briefly, the SMARTer first
strand synthesis was performed using the SMARTer II A oligonucleotide (AAG
CAGTGGTATCAACGCAGAGTACXXXXX; X = undisclosed base in the proprietary
SMARTer ologo sequence). The sequence of HBV specific RT primer was 50-CGA
GATTGAGATCTTCTGCGAC-30 . The sequences of HBV specific reverse primers used
for semi-nested PCR were: R1: 50-GTTGATAAGATAGGGGCATTTGGTGGTC-30 , and
R2: 50-GAAGGAAAGAAGTCAGAAGGCAA-30 . Both of forward primer was: 50-CTAA
TACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-30 .
Statistical analyses
The repeated measures analysis of variance and two groups of related non-
parameters Wilcoxon symbols test were performed using the statistical software
package SPSS version 21.0 for Windows (SPSS, Chicago, IL, USA). All tests of sig-
nificance were two-tailed and p <0.05 was considered statistically significant.Results
Serum HBV RNA is pregenome RNA
We systematically investigated the nature of the serum-
associated HBV RNA in order to better understand its clinical sig-
nificance. First, the levels of HBV DNA and HBV RNA in sera of 11
treatment-naïve CHB patients (cohort A) were determined by
quantitative real-time PCR (qPCR) or RT-PCR (RT-qPCR). The med-
ian baseline levels of HBV DNA and HBV RNA in serum were 7.87
(6.56–9.01) log10 copies/ml and 6.31 (5.10–8.02) log10 copies/ml,
respectively. Thus, the presence of serum HBV RNA was demon-
strated in the sera of CHB patients, though HBV RNA levels were
significantly lower than HBV DNA levels (p = 0.007, Fig. 1A). Total
HBV RNA and 3.5 kb HBV RNA levels in the sera of three
treatment-naïve CHB patients were subsequently analyzed by
RT-qPCR. The efficiency of RT-qPCR for 3.5 kb HBV RNA or total
HBV RNA is shown in each standard curve (Supplementary
Fig. 1). To rule out interference from residual HBV DNA, samples
were treated with DNase I before reverse transcription was per-
formed. The level of 3.5 kb HBV RNA was almost equal to that
of total HBV RNA in all three patients, suggesting that 3.5 kb
HBV RNA was the predominant type of HBV RNA present in
serum (Fig. 1B). The qPCR results were confirmed by northern
blot analysis, and demonstrated that only the 3.5 kb RNA could
be detected in the supernatant of untreated HepAD38 cells
(Fig. 1C). Collectively, these data indicate that the 3.5 kb RNA is
the only HBV RNA present in patient sera.
The 3.5 kb HBV RNA represents both preC mRNA and pgRNA.
In order to clearly identify the 3.5 kb HBV RNA detected in serum,
we performed multiple identification PCRs. We used 3.5 kb HBV
RNA-specific primers that amplify both preC mRNA and pgRNA
and preC mRNA specific primers that only amplify preC mRNA
(Fig. 1D). The discriminatory specificities of the designed primers
were first confirmed with RNAs extracted from HBV producing
cell lines including HepAD38 and HepG2.2.15 cells. As shown in
Fig. 1E, the specific primers could efficiently amplify preC mRNA
and 3.5 kb HBV RNA from cell lysates, respectively. Only the
3.5 kb HBV RNA, and not preC mRNA, was detected in the super-
natants of either HepAD38 or HepG2.2.15 cells, even after treat-
ment with ETV. ETV treatment resulted in a large increase in
the level of 3.5 kb HBV RNA, which indicated that just pgRNA
was present in the culture supernatant. Consistent with this
observation, only pgRNA was detected in the sera of three
treatment-naïve CHB patients, confirming that the HBV RNA
detected in serum is pgRNA (Fig. 1F).Journal of Hepatology 201Serum HBV pgRNA is present in HBV-like viral particles
Several studies have reported that the HBV RNA detected in
serum may be incorporated into HBV particles [9,12], although
its precise form is poorly understood. In order to address this,
HepAD38 cell supernatant was treated with NP-40 to remove
the lipid membrane bound structures or with proteinase K to
destroy the proteinaceous structure. HBV RNA was only detected
in the supernatant treated with proteinase K, indicating that HBV
RNA in HepAD38 supernatant was contained within a proteina-
ceous structure, most likely in the nucleocapsids (Fig. 2A). Consis-
tent with previous observations (Fig. 1E), the level of HBV RNA
detected following proteinase K treatment was much higher in
the supernatant of HepAD38 cells treated with ETV as compared
to untreated cells (Fig. 2A).
Supernatant of both untreated and ETV-treated HepAD38 cells
was subjected to PEG-precipitation followed by sucrose density
gradient centrifugation, with the levels of HBsAg, HBcAg and
HBV DNA in each gradient fraction analyzed. As shown in
Fig. 2B, HBV DNA peaked in fraction 26 for both untreated and
ETV-treated samples. Similarly, HBcAg also peaked in fraction
26, suggesting that HBV viral particles were enriched in this frac-
tion (Fig. 2C). The HBsAg was enriched in fractions 18–25, sug-
gesting that HBV filaments and spheres were concentrated in
these fractions (Supplementary Fig. 2). The HBV RNA had a sim-
ilar fraction distribution as HBV DNA and HBcAg, suggesting that
the HBV RNA detected in the supernatant of HepAD38 cells or in
the serum of CHB patient was incorporated into HBV-like viral
particles (Fig. 2B). To further confirm this observation, we mea-
sured the changes of HBV DNA, RNA and HBcAg levels in the
supernatant of ETV-treated HepAD38 cells. We postulated that
if HBV particles consist of only HBV DNA, then the levels of HBcAg
should decline to the same degree as that of HBV DNA in
ETV-treated HepAD38 cell supernatants. Results show that
HBcAg levels did not change significantly, indicating that HBV
particle’s composition was not limited to HBV DNA (Fig. 2D;
Supplementary Fig. 3). Parallel analysis of HBV DNA and
HBV RNA revealed that while HBV DNA levels were
dramatically reduced in HepAD38 supernatants in the presence
of ETV (5.94 ± 0.03 log10 copies/ml) compared to untreated
cells (7.01 ± 0.04 log10 copies/ml), the levels of HBV RNA
increased more than 10-fold (5.91 ± 0.06 log10 copies/ml vs.
7.00 ± 0.03 log10 copies/ml). Of particular note was the finding
that HBV RNA levels in the ETV-treated HepAD38 cell super-
natants (7.00 ± 0.03 log10 copies/ml) was almost equal to that of
HBV DNA levels in untreated HepAD38 cell supernatants
(7.01 ± 0.04 log10 copies/ml). These results combined with the
observation that HBcAg levels remain unchanged in ETV-treated
HepAD38 cell supernatants provide further evidence that HBV
RNA is present in HBV-like viral particles (Fig. 2D).
Previous reports indicate that viral RNA can be present in exo-
somes [27,28]. In order to determine if our results are due to
exosome-associated HBV RNA, we treated HepAD38 cells with
GW4869, a known inhibitor of exosome secretion. GW4869 treat-
ment reduced the expression of exosome-specific protein CD63
but did not affect the levels of HBV RNA (Fig. 2E), indicating that
serum HBV RNA is not associated with exosomes. Additionally,
electron microscopy of fraction 26 showed that similar HBV-
like viral particles were present in both ETV-treated and
untreated HepAD38 cell supernatants (Fig. 2F). Given that the
levels of HBV DNA and RNA are different in these samples, this6 vol. 65 j 700–710 703
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Fig. 1. Identification on the nature of HBV RNA in serum. (A) HBV DNA and HBV RNA levels in the sera of treatment-naïve CHB patients (n = 11) were detected by qPCR or
RT-qPCR. (B) The levels of total HBV RNA and 3.5 kb HBV RNA in the sera of three treatment-naïve CHB patients were detected by RT-qPCR. (C) HBV RNA in HepAD38 cells or
in the supernatant of HepAD38 cells was detected by northern blot. The supernatant (300 ml) of HepAD38 cells was PEG-precipitated to concentrate HBV before extracting
HBV RNA. (D) The diagram of multiple identification PCRs, in which the transcription starting sites (TSS) of preC mRNA (PC) and pgRNA (at the nucleotide 1818 or 1819 in
HBV genome) are indicated according to the reference sequence of HBV genome from GenBank (Accession AB014381). The sequence of preC mRNA specific forward primer
is shown in the red box. (E) The levels of preC mRNA (PC) and 3.5 kb HBV RNA in HepAD38 and HepG2.2.15 cells, the supernatant of HepAD38 and HepG2.2.15 cells, or the
sera of three treatment-naïve CHB patients were detected by multiple identification PCRs (F). (This figure appears in colour on the web.)
Research Articledata provides further supporting evidence that HBV RNA is pre-
sent in HBV-like viral particles likely as HBV pgRNA virions.
To further confirm that the RNA presented in HBV-like viral
particles is pgRNA, the 50 end of HBV RNA in fraction 26 was ana-
lyzed using 50RACE-based PCR and clonal sequencing assay. As
shown in Fig. 2G, HBV RNA in fraction 26 was indeed pgRNA tran-
scribed from nucleotide 1818 or 1819 in HBV genome (for details,
refer to Fig. 1D).
To provide further evidence that HBV pgRNA virions in super-
natants was produced by the encapsidated pgRNA, HepAD38 cells
were treated with GLS4, a capsid assembly modifier that inter-
feres with the HBV capsid assembly process and reduces HBV
replication [23,29]. Specifically, GLS4 disrupts the HBV lifecycle
by inducing the assembly of defective capsids and blocking
pgRNA encapsidation, as demonstrated by the decreased level
of intracellular encapsidated pgRNA, and consequently intracel-
lular and extracellular encapsidated HBV DNA (Fig. 2H and
Supplementary Fig. 4). Extracellular HBeAg level also decreased704 Journal of Hepatology 201due to GLS4-induced inhibition of intracellular encapsidated
HBV DNA and subsequently decreased the cccDNA pool
(Supplementary Fig. 5). After the treatment of GLS4, the
decreased level of pgRNA virions and core protein in supernatant
indicated that serum pgRNA virions were packaged by capsid
protein (Fig. 2I; Supplementary Fig. 3).
Suppression of the reverse transcription activity of HBV DNA
polymerase increases the level of HBV pgRNA virions in vitro
Given that pgRNA is a component of the HBV virion and the only
encapsidated HBV RNA in the cytoplasm [30], we hypothesize
that HBV pgRNA virion might originate from the non- or partially
reverse transcribed pgRNA encapsidated in the cytoplasm. As
pgRNA would normally be degraded during the process of reverse
transcription, an increase of HBV RNA virion should be expected
following inhibition of reverse transcription. We tested this by
measuring HBV pgRNA virion levels following NA-mediated block6 vol. 65 j 700–710
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JOURNAL OF HEPATOLOGYin HBV reverse transcription. Indeed, the levels of HBV pgRNA vir-
ion in the supernatant increased in a dose-dependent manner
when HepAD38 cells were treated with ETV and lamivudine
(LMV). A dramatic decrease in the level of HBV DNA was alsoJournal of Hepatology 201observed (Fig. 3A; Supplementary Fig. 6). This effect was also
observed in HepG2.2.15 cells (Fig. 3B). The decrease in HBV
DNA levels and increase in HBV pgRNA virion levels also occurred
in a time-dependent manner in the supernatant of either6 vol. 65 j 700–710 705
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Research ArticleHepAD38 and HepG2.2.15 cells treated with ETV for different
times (2, 4, 6 and 8 days) (Fig. 3C and D). However, cytoplasmic
encapsidated HBV RNA levels in HepAD38 cells either remained
unchanged or increased upon ETV treatment (Fig. 3E). HBV
pgRNA virion levels in the supernatant of primary human hepa-
tocytes (PHH) infected with HBV also significantly increased after
ETV treatment (Fig. 3F).
In addition to blocking HBV reverse transcription by NAs, a
priming reaction-deficient TP-Y63F mutant (Y63F) was con-
structed that could encapsidate pgRNA, but could not efficiently706 Journal of Hepatology 201generate rcDNA [31]. Consistent with this concept, the level of
HBV pgRNA virion in the supernatant of HuH7 cells transiently
transfected with the Y63F mutant construct was significantly
higher than that of its wild-type counterpart (p <0.001) (Fig. 3G).
Suppression of the reverse transcription activity of HBV DNA
polymerase increases the levels of HBV pgRNA virion in vivo
In addition to the in vitro experiments described, the origin of
HBV pgRNA virion in HBV transgenic mice was analyzed. Eight6 vol. 65 j 700–710
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Fig. 4. The origin of HBV pgRNA virion was determined in vivo. HBV DNA (A)
and HBV pgRNA virion (B) levels in the sera of 6-week-old female HBV transgenic
mice (n = 8) were detected by qPCR or RT-qPCR at ETV pre-treatment (Baseline), 9
and 17 days post ETV (3.2 mg/kg) treatment. Statistical analyses were performed
by the repeated measures analysis of variance. (C) The pre-therapy and post-
therapy levels of HBV DNA and HBV pgRNA virions in the sera of CHB patients
(n = 11) were detected in parallel by qPCR and RT-qPCR, respectively. (D) The pre-
therapy and post-therapy HBV RNA/DNA ratios in the sera of CHB patients
(n = 11). Statistical analyses were performed by the two groups of related non-
parameters Wilcoxon symbols test, as the data of the two groups was not
subjected to normal distribution and highly relevant.
JOURNAL OF HEPATOLOGYHBV transgenic mice were treated with 3.2 mg/kg of ETV or a sol-
vent placebo by oral gavage once per day. Blood was sampled
from the angular vein at three time points, at ETV pre-
treatment (baseline), 9 and 17 days post ETV treatment, and the
levels of HBV DNA and HBV pgRNA virion were determined by
qPCR and RT-qPCR. As shown in Fig. 4A, the levels of HBV DNA
in the sera of HBV transgenic mice significantly decreased at 9
and 17 days post ETV treatment compared to baseline levels
(p = 0.0043 and 0.0040, respectively). In contrast, the levels of
HBV pgRNA virion increased significantly at the same time points
(p = 0.0211 and 0.0429, respectively), consistent with the results
of in vitro experiments (Figs. 3A and B, 4B). No significant changes
of either HBV DNA or HBV pgRNA virion in the sera of the solvent
placebo controls were observed (data not shown).
The pre-therapy and post receiving NA-therapy levels of HBV
DNA and HBV pgRNA virion in serum were subsequently deter-
mined in a cohort of telbivudine (TBV)-treated CHB patients
(cohort A, n = 11) by qPCR and RT-qPCR, respectively. The
level of HBV DNA virion significantly decreased from 7.87
(6.56–9.01) log10 copies/ml at pre-therapy to 3.51 (1.76–7.13)
log10 copies/ml (p = 0.0002) at different times after receiving
NA-therapy. Although the level of HBV pgRNA virion also
significantly decreased from 6.31 (5.10–8.02) log10 copies/ml toJournal of Hepatology 2014.73 (1.74–7.24) log10 copies/ml after the long-term of TBV treat-
ment (p = 0.0071), its level declined much less than HBV DNA
(Fig. 4C). Therefore, we use the ratio of HBV pgRNA virion to
HBV DNA (HBV RNA/DNA) to reflect the changing pattern, and
the ratio was found to be increased significantly following NA-
therapy (p <0.0001, Fig. 4D).
Since NA-mediated HBV polymerase inhibition blocks HBV
replication through blocking the generation of rcDNA reversely
transcribed from pgRNA, they may not inhibit the generation of
HBV pgRNA virions. We theorized that the presence of pgRNA vir-
ion in patient’s serum should reflect the presence and transcrip-
tional activity of cccDNA in patient liver. In order to investigate
whether HBV pgRNA virion was associated with risk of viral
rebound after the end of treatment (EoT), 33 CHB patients (cohort
B) who received standard NAs treatment and with HBV DNA
levels below the lower limit of detection (LoD) at EoT were fol-
lowed up. Among these CHB patients, the levels of serum HBV
RNA were positive in 21 (63.64%) patients, and 12 (36.36%)
patients had serum HBV RNA levels below the LoD. On the basis
of HBV DNA re-appearance at 24 weeks post of EoT, viral rebound
occurred in 21 (100%) patients whose HBV RNA was positive at
EoT, whereas, only in 3 (25%) of the 12 patients whose HBV
RNA levels were below the LoD. It is worthwhile to consider that
the level of HBV pgRNA virion might be associated with risk of
HBV viral rebound after discontinuation of NA-therapy
(p = 0.001) (Table 3).Discussion
This study aimed to thoroughly investigate observations in previ-
ous studies suggesting that HBV RNA in the sera of treatment-
naïve CHB patients might be pgRNA [9,10]. Because it is generally
believed that HBV DNA synthesis is required for nucleocapsid
maturation and envelopment [32,33], one may argue that
without initiation of reverse transcription, the encapsidated
pgRNA/P protein complex could not be enveloped and properly
secreted. However, several studies have suggested that the
nucleocapsid maturation may not be DNA synthesis-dependent
[34–36] and genome-free HBV virions were also detected in the
sera of CHB patients, supporting the presence of non-classical
HBV packaging pathway in which DNA synthesis may not be
needed [37,38].
An important first question to address is the nature of serum
HBV RNA detected in CHB patients (Fig. 1). A series of experi-
ments in several cell types and different compounds, revealed
the detected serum HBV RNA is only pgRNA. Northern blot iden-
tified the RNA as 3.5 kb RNA, then multiple identification PCRs
and 50 RACE experiments specifically found the RNA to be pgRNA
and not preC mRNA (Figs. 1 and 2). Importantly, this pgRNA orig-
inates from encapsidated virions as demonstrated by utilizing
proteinase K treatment, sucrose gradient centrifugation, electron
microscopy, as well as GLS4 treatment (Fig. 2). Furthermore, we
detected HBV pgRNA virions in the supernatants of HepAD38
and HepG2.2.15 cells. Since hepatoma cells have a particular
behavior in terms of viral particle secretion, for example, the
nonenveloped nucleocapsids are often found after transfection
of hepatoma cells with efficient HBV expression constructs [39],
we also detected HBV pgRNA virion in supernatants of PHH. It
should also be noted that the levels of HBV pgRNA virion
increased upon ETV treatment (Fig. 3).6 vol. 65 j 700–710 707
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Research ArticleThe level of HBV pgRNA virion in HBV transgenic mice also
significantly increased after ETV treatment (Fig. 4). Importantly,
the level of HBV pgRNA virion declined much slower than HBV
DNA did in most CHB patients after receiving NA-therapy, and
the ratio of HBV pgRNA virions to HBV DNA (HBV RNA/DNA)
was significantly increased, indirectly reflecting that the level of
pgRNA virion increase. This is further bolstered by the fact that
the HBV Y63F mutant, which is deficient for the reverse tran-
scription of pgRNA, but not for its encapsidation, could produce
more HBV pgRNA virions than wild-type virions. Collectively,
these results indicate that a block in reverse transcription of
pgRNA leads to an obvious increase in HBV pgRNA virions extra-
cellularly. Based on these observations, we propose a model
where the presence of HBV pgRNA virion provides a supplemen-
tary process during the HBV lifecycle (Fig. 5). Encapsidated
pgRNA in the cytoplasm of hepatocytes would be enveloped
and released into the serum of treatment-naïve CHB patient as
HBV pgRNA virion. Following NA-treatment, reverse transcription
would be inhibited, and the pgRNA in core particles would still be
enveloped and released into the serum, thereby increasing the
level of HBV pgRNA virions. Our postulation that HBV pgRNA viri-
ons could be both encapsidated and enveloped was further sup-
ported by the direct association of HBV pgRNA with HBsAg in
the supernatant of HepG2.2.15 cells through immunoprecipita-
tion with HBsAg-specific antibodies. Moreover, the amount of
HBV pgRNA precipitated by HBcAg-specific antibodies in the sera
of CHB patients increased approximately 100-fold after removal
of the HBsAg envelope [9]. These data, together with our current
results, suggest that HBV pgRNA virions are both encapsidated
and enveloped. Nonetheless, it is important to emphasize thatTable 3. The association of HBV pgRNA virion levels and viral rebound after
the discontinuation of NAs-therapy.
HBV RNA Viral
rebound (n)
No viral
rebound (n)
Total
(n)
*p value
Positive 21 0 21
Below the LoQ 3 9 12 0.001
Total (n) 24 9 33
⁄Chi-Square test; n, number of CHB patients.
708 Journal of Hepatology 201more evidence is needed to further demonstrate HBV pgRNA viri-
ons are indeed enveloped.
Generally, a virus can be classified either as a DNA virus or
RNA virus based on the nucleic acid composition of the viral gen-
ome. Accordingly, HBV has traditionally been defined as a
double-stranded DNA virus. The discovery of HBV pgRNA virion
implies that HBV may have another natural virion form in which
the nucleic acid is composed of pgRNA, not the rcDNA. It is well
known that hepatitis D virus (HDV) is a defective RNA virus that
requires HBV envelope proteins for the production of infectious
virus particles [40,41]. We hypothesize that similar to HDV, the
enveloped HBV pgRNA virion has the potential to infect hepato-
cytes. Given that the HBV pgRNA virion contains both the P pro-
tein and the pgRNA, it is possible that upon entry into
hepatocytes HBV rcDNA is reversely transcribed in the cytoplasm
from the nucleocapsid pgRNA. Subsequently, core particles con-
taining rcDNA can enter into the nucleus to form cccDNA, or
can be enveloped and secreted to form Dane’s particle. Thus, it
is possible that HBV pgRNA virions can re-infect hepatocytes
and contribute to persistence of HBV infection. Unfortunately,
at this time, it is technically too difficult to isolate pure HBV
pgRNA virions to confirm such a postulation. To further under-
stand the biological relevance of HBV pgRNA virions, critical
issues including the phosphorylation status of capsids, overall
infectivity and role in immunopathology should be addressed
in the future.
A potential clinical significance of HBV pgRNA virions was also
observed in this study. Given that NAs have no or little effect on
the transcription of cccDNA, it is possible that HBV pgRNA virions
may be continuously produced due to the persistence of cccDNA,
even if HBV DNA virus is undetectable. Detection of pgRNA viri-
ons in serum may reflect the presence and active transcription
of cccDNA in the liver of patients, and in the case of NA-
therapy, constant undetectable level of serum HBV pgRNA may
serve as a predictive biomarker to guide the safe discontinuation
of NA-therapy. In this study, serum HBV pgRNA was detected in
33 CHB patients whose HBV DNA virus was undetectable at the
EoT. It is important to note that HBV pgRNA virion was still pos-
itive in the sera of 21 CHB patients, and viral rebound occurred in
all these patients (21/21) at 24 weeks post treatment. Whereas
among the 12 CHB patients whose HBV pgRNA virion was6 vol. 65 j 700–710
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undetectable, viral rebound only occurred in 3 patients, thereby
strongly suggesting that HBV pgRNA virion might be associated
with risk of viral rebound after the discontinuation of NA-
therapy. It will be an important future task to use a large patient
cohort to further determine the association of HBV pgRNA virion
with risk of viral rebound.
In conclusion, we performed a series of experiments and iden-
tified that HBV RNA in serum is pgRNA that is encapsidated and
present in HBV-like viral particles. The discovery of HBV pgRNA
virion provides another level of complexity to the HBV lifecycle,
where in addition to HBV DNA, encapsidated pgRNA can also be
enveloped and secreted out of the cell. Clinically, our data reveals
that the level of HBV pgRNA virion in serum may be associated
with risk of HBV viral rebound after withdrawal of treatment,
and therefore, a potential predictive biomarker to monitor the
safe discontinuation of NA-therapy.Financial support
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